LEADER 01693nam  2200421   450 
001 9910707255503321
005 20160614081836.0
035   $a(CKB)5470000002462953
035   $a(OCoLC)951671365
035   $a(OCoLC)995470000002462953
035   $a(EXLCZ)995470000002462953
100   $a20160614d2013      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aFDA lacks comprehensive data to determine whether risk evaluation and mitigation strategies improve drug safety
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2013.
215   $a1 online resource (34 pages) $cillustrations
300   $aTitle from title screen (viewed June 13, 2016).
300   $a"February 2013."
300   $a"OEI-04-11-00510."
320   $aIncludes bibliographical references.
517 3 $aFood and Drug Administration lacks comprehensive data to determine whether risk evaluation and mitigation strategies improve drug safety
517 1 $aFDA lacks comprehensive data to determine whether REMS improve drug safety
606   $aMedicare
606   $aDrugs$xRisk assessment$zUnited States$xEvaluation
606   $aDrugs$zUnited States$xSafety measures$xEvaluation
615  0$aMedicare.
615  0$aDrugs$xRisk assessment$xEvaluation.
615  0$aDrugs$xSafety measures$xEvaluation.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707255503321
996   $aFDA lacks comprehensive data to determine whether risk evaluation and mitigation strategies improve drug safety$93348157
997   $aUNINA